---
id: 202
title: Infective Endocarditis - Duke Criteria and Management
category: clinical_syndromes
subcategory: cardiovascular
tags: [endocarditis, IE, Duke-criteria, TEE, viridans-strep, S-aureus, prosthetic-valve]
difficulty: high
---

## Question

How is IE diagnosed and treated? Use **"Duke: 2 Major (Blood Cx + Echo) or 1 Major + 3 Minor, Native: PCN 4wk, Prosthetic: 6wk, Surgery if CHF/Abscess"** framework.

## Answer

### **Modified Duke Criteria:**

**Major Criteria:**

1. **Positive Blood Cultures:**
   - **Typical IE organisms** in ≥2 separate cultures: Viridans strep, *S. aureus*, *S. gallolyticus* (formerly *bovis*), HACEK, enterococci, community-acquired *S. lugdunensis*
   - **Persistently positive** blood cultures (≥2 drawn >12h apart OR all 3/majority if ≥4 drawn)
   - **Single positive** for *Coxiella burnetii* (Q fever) OR anti-phase I IgG titer >1:800

2. **Evidence of Endocardial Involvement (Echo):**
   - **Vegetation** (oscillating intracardiac mass on valve/supporting structures)
   - **Abscess** (perivalvular)
   - **New partial dehiscence** of prosthetic valve
   - **New valvular regurgitation** (change from baseline)

**Minor Criteria:**
- **Predisposing condition:** Prosthetic valve, congenital heart disease, IVDU, prior IE
- **Fever:** ≥38°C (100.4°F)
- **Vascular phenomena:** Arterial emboli, septic pulmonary infarcts, mycotic aneurysm, intracranial hemorrhage, Janeway lesions
- **Immunologic phenomena:** Glomerulonephritis, Osler nodes, Roth spots, positive rheumatoid factor
- **Microbiologic evidence:** Positive blood culture not meeting major criteria

**Definite IE:**
- **2 major** OR **1 major + 3 minor** OR **5 minor**

**Possible IE:**
- **1 major + 1 minor** OR **3 minor**

### **Clinical Presentation:**

**Classic Triad (Only 10-15%):**
- **Fever, new murmur, embolic phenomena**

**Common:**
- **Fever** (80-90%)
- **New or worsening murmur** (85%)
- **Embolic events** (20-50%): Stroke, splenic/renal infarcts, septic pulmonary emboli (right-sided)

**Peripheral Stigmata (Rare, <10%):**
- **Osler nodes:** Tender nodules on finger/toe pads
- **Janeway lesions:** Painless hemorrhagic macules on palms/soles
- **Roth spots:** Retinal hemorrhages with pale centers
- **Splinter hemorrhages:** Subungual linear hemorrhages

### **Diagnosis:**

**Blood Cultures:**
- **≥3 sets** (aerobic + anaerobic) from separate sites before antibiotics
- **Hold 5-7 days** (for fastidious organisms like HACEK)

**Echocardiography:**

**TTE (Transthoracic):**
- **First-line** (non-invasive)
- **Sensitivity:** 60-70% (native valve), 40-50% (prosthetic valve)

**TEE (Transesophageal):**
- **Indicated if:** High clinical suspicion + negative TTE, prosthetic valve, suspected abscess, poor TTE windows
- **Sensitivity:** 90-95% (superior to TTE)

**Repeat Echo:**
- **If initial negative** but high suspicion → repeat TEE in 7-10 days

### **Treatment:**

**Native Valve Endocarditis (NVE):**

**Viridans Streptococci / *S. gallolyticus* (PCN-Susceptible, MIC ≤0.12):**
- **Penicillin G 12-18 million units IV daily (divided q4h) OR ceftriaxone 2g IV daily × 4 weeks**
- **OR:** Penicillin/ceftriaxone × 2 weeks + gentamicin 3 mg/kg IV daily × 2 weeks (uncomplicated only)

***S. aureus* (MSSA):**
- **Nafcillin 2g IV q4h OR cefazolin 2g IV q8h × 6 weeks**
- **Consider adding gentamicin** × first 3-5 days (controversial, increases nephrotoxicity)

***S. aureus* (MRSA):**
- **Vancomycin 15-20 mg/kg IV q8-12h × 6 weeks**
- OR **daptomycin 8-10 mg/kg IV daily × 6 weeks** (some prefer daptomycin, no nephrotoxicity with aminoglycoside)

**Enterococci:**
- **Ampicillin 2g IV q4h** (if ampicillin-susceptible) + **gentamicin 1 mg/kg IV q8h** OR **ceftriaxone 2g IV q12h** × 4-6 weeks
- **VRE:** Daptomycin 10-12 mg/kg IV daily OR linezolid 600mg IV/PO BID (6-8 weeks)

**HACEK:**
- **Ceftriaxone 2g IV daily × 4 weeks** (6 weeks if prosthetic valve)

**Prosthetic Valve Endocarditis (PVE):**
- **Longer duration:** 6 weeks minimum
- **Add rifampin** (biofilm): 300mg PO TID (for staphylococci, start after wound healing if early PVE)
- **Consider combination therapy** (e.g., vancomycin + gentamicin + rifampin for CoNS)

### **Surgical Indications:**

**Urgent/Emergent Surgery (<24-48h):**
- **Heart failure** (valve dysfunction, severe regurgitation)
- **Perivalvular extension** (abscess, fistula, heart block)
- **Uncontrolled infection** (persistent bacteremia >5-7 days, fungal IE, resistant organisms)

**Elective Surgery (After Antibiotics):**
- **Recurrent emboli** despite appropriate antibiotics
- **Large vegetations** (>10 mm, especially with embolic event)
- **Prosthetic valve dysfunction**

**Embolic Stroke:**
- **Delay surgery 2-4 weeks** if possible (risk of hemorrhagic transformation with anticoagulation during CPB)

### **Anticoagulation:**

**Avoid Initiating** warfarin/heparin (does NOT prevent emboli, increases ICH risk)

**If Already on Anticoagulation:**
- **Mechanical valve:** Continue (required for valve)
- **Atrial fibrillation:** Case-by-case (consider stopping if high ICH risk)

### **Complications:**

**Heart Failure:**
- **Most common cause of death** (valve destruction, perivalvular extension)
- **Surgery often needed**

**Embolic Events:**
- **Stroke** (15-20%, especially *S. aureus*)
- **Splenic/renal infarcts, mycotic aneurysm**

**Perivalvular Extension:**
- **Abscess, fistula** (especially aortic valve IE, *S. aureus*)
- **Conduction abnormalities** (heart block) → suggests abscess

## Key Points

### **Duke Criteria:**
- **Definite IE:** 2 major OR 1 major + 3 minor OR 5 minor
- **Major:** Positive cultures (typical organisms, persistent) + echo (vegetation, abscess, new regurgitation)

### **TEE > TTE:**
- **TEE sensitivity 90-95%** (especially prosthetic valve, abscess)
- **Repeat TEE in 7-10 days** if high suspicion + negative initial

### ***S. aureus* = Highest Mortality:**
- **Nafcillin/cefazolin × 6 weeks** (MSSA)
- **Vancomycin/daptomycin × 6 weeks** (MRSA)
- **High complication rate** (emboli, abscess, metastatic foci)

### **Surgery Indications:**
- **CHF** (valve dysfunction) = most common, urgent
- **Perivalvular abscess** (heart block suggests abscess)
- **Uncontrolled infection** (persistent bacteremia >5-7 days, fungal)
- **Recurrent emboli**

### **Prosthetic Valve:**
- **6 weeks antibiotics** (vs. 4 weeks native)
- **Add rifampin** for staphylococci (biofilm)

### **Clinical Pearls:**
- **Duke:** 2 major (cultures + echo) OR 1 major + 3 minor
- **TEE** if prosthetic valve, abscess suspected, negative TTE with high suspicion
- ***S. aureus*:** Nafcillin (MSSA) or vancomycin/daptomycin (MRSA) × 6 weeks
- **Surgery:** CHF, abscess, persistent bacteremia >5-7 days
- **Prosthetic valve:** 6 weeks + rifampin (staphylococci)

## Sources

- [AHA: Infective Endocarditis Guidelines 2024]
- [ESC: Endocarditis Management 2024]

## Media

N/A
